person · Reporting owner
Arbet-Engels Christophe
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Medical Officer | October 01, 2026 | October 05, 2026 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Chief Medical Officer | May 25, 2020 | May 28, 2020 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Medical Officer | February 12, 2025 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 24,821 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 37,500 · Balance 37,500 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-10-01 · Tax withholding · Disposed 12,679 · Balance 24,821 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 112,500 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 37,500 · Balance 112,500 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Tempest Therapeutics, Inc.
Report date May 25, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-05-24 | Direct | 80,000 |
Reported balance
After 2020-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-25 · Grant · Acquired 80,000 · Balance 80,000 F1: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.
X4 Pharmaceuticals, Inc
Report date February 12, 2025 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 864,207 |
Reported balance
After 2025-02-12 transaction · row 1
1 source rowRow 1 · 2025-02-12 · Grant · Acquired 850,000 · Balance 864,207 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001802615-26-000002 · form4-10052026_041009.xml · derivative · entry 3 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock, par value $0.0001 · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 12,679 | $2.76 | $34,994.04 |
DisclosureSEC source: 0001802615-26-000002 · form4-10052026_041009.xml · nonDerivative · entry 2 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,821 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001802615-26-000002 · form4-10052026_041009.xml · nonDerivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:23 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-096678 · tm2527887-2_4seq1.xml · derivative · entry 2 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock, par value $0.0001 · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:23 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 450,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001104659-25-096678 · tm2527887-2_4seq1.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock, par value $0.0001 · 450,000 shares Expires 2035-10-01 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-005704 · wk-form4_1739567336.xml · nonDerivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,207 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 11,624 | $0.45 | $5,284.27 |
DisclosureSEC source: 0001628280-25-002705 · wk-form4_1738019705.xml · nonDerivative · entry 2 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,207 F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4478 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 25,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-002705 · wk-form4_1738019705.xml · nonDerivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,831 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 22:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 475,831 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005385 · wk-form4_1708121451.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,831 Underlying: Common Stock · 475,831 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 28, 2024 22:52 UTC Amendment | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 180,816 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-007711 · wk-form4a_1709160742.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,816 Underlying: Common Stock · 180,816 shares Expires 2034-02-13 F1 · shares: This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error. F2 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 1,250,000 | $1.28 Strike: $1.28 | $1,600,000.00 |
DisclosureSEC source: 0001628280-23-031389 · wk-form4_1693944923.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2033-08-30 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 25, 2020 Filed May 28, 2020 01:38 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032486 · doc4.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-05-24 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 22:02 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-20-008370 · doc4.xml · derivative · entry 1 Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on February 10, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the recipient continuing to provide service through that date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.